Compare OWLT & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OWLT | CNTB |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | 114 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.7M | 135.7M |
| IPO Year | N/A | 2020 |
| Metric | OWLT | CNTB |
|---|---|---|
| Price | $5.58 | $2.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $17.50 | $8.67 |
| AVG Volume (30 Days) | 232.6K | ★ 677.5K |
| Earning Date | 05-07-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | $22.81 | N/A |
| Revenue Next Year | $20.45 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.19 | $1.23 |
| 52 Week High | $16.94 | $3.82 |
| Indicator | OWLT | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 52.26 |
| Support Level | $5.26 | $2.17 |
| Resistance Level | $6.23 | $2.75 |
| Average True Range (ATR) | 0.47 | 0.23 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 17.91 | 33.58 |
Owlet Inc is engaged in providing a digital parenting platform that aims to give parents real-time data and insights to help parents feel more calm and confident. Its diversified portfolio of products includes Owlet Smart Sock, the first baby monitor to track an infant's oxygen levels, heart rate, and sleep trends; the Owlet Cam, which turns any smartphone into a baby monitor with high-definition clarity; the Owlet Monitor Duo, which offers the intelligence of the Owlet Smart Sock paired with the Owlet Cam; and Owlet Dream Lab, an interactive online program designed to be a parent's guide to building healthy sleep habits for their infants.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.